vs
Axogen, Inc.（AXGN）与LivaNova PLC（LIVN）财务数据对比。点击上方公司名可切换其他公司
LivaNova PLC的季度营收约是Axogen, Inc.的6.0倍（$360.9M vs $59.9M）。LivaNova PLC净利率更高（8.6% vs -22.0%，领先30.5%）。Axogen, Inc.同比增速更快（21.3% vs 12.1%）。LivaNova PLC自由现金流更多（$50.2M vs $1.8M）。过去两年Axogen, Inc.的营收复合增速更高（20.3% vs 10.6%）
Axogen总部位于美国佛罗里达州阿拉楚阿，是外科解决方案提供商，专注开发周围神经损伤修复相关产品，涵盖人体组织移植物、神经连接器、软组织膜等，旗下AVANCE细胞移植技术可模拟人体神经结构，临床数据显示其产品帮助87%的周围神经损伤患者实现感觉与运动功能恢复，2013年完成1800万美元首次公开募股。
LivaNova PLC是一家深耕医疗设备领域的企业，总部位于英国，核心业务为研发心脏外科及神经调控类医疗设备。该公司由美国Cyberonics公司与意大利Sorin公司于2015年以27亿美元对价合并成立，目前在纳斯达克挂牌交易，股票代码为LIVN。
AXGN vs LIVN — 直观对比
营收规模更大
LIVN
是对方的6.0倍
$59.9M
营收增速更快
AXGN
高出9.1%
12.1%
净利率更高
LIVN
高出30.5%
-22.0%
自由现金流更多
LIVN
多$48.4M
$1.8M
两年增速更快
AXGN
近两年复合增速
10.6%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $59.9M | $360.9M |
| 净利润 | $-13.2M | $30.9M |
| 毛利率 | 74.1% | 65.2% |
| 营业利润率 | -16.3% | 11.8% |
| 净利率 | -22.0% | 8.6% |
| 营收同比 | 21.3% | 12.1% |
| 净利润同比 | -3023.6% | -44.7% |
| 每股收益（稀释后） | $-0.28 | $0.57 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AXGNLIVN
| Q4 25 | $59.9M | $360.9M | ||
| Q3 25 | $60.1M | $357.8M | ||
| Q2 25 | $56.7M | $352.5M | ||
| Q1 25 | $48.6M | $316.9M | ||
| Q4 24 | $49.4M | $321.8M | ||
| Q3 24 | $48.6M | $318.1M | ||
| Q2 24 | $47.9M | $318.6M | ||
| Q1 24 | $41.4M | $294.9M |
净利润AXGNLIVN
| Q4 25 | $-13.2M | $30.9M | ||
| Q3 25 | $708.0K | $26.8M | ||
| Q2 25 | $579.0K | $27.2M | ||
| Q1 25 | $-3.8M | $-327.3M | ||
| Q4 24 | $450.0K | $55.9M | ||
| Q3 24 | $-1.9M | $33.0M | ||
| Q2 24 | $-1.9M | $16.3M | ||
| Q1 24 | $-6.6M | $-41.9M |
毛利率AXGNLIVN
| Q4 25 | 74.1% | 65.2% | ||
| Q3 25 | 76.6% | 68.4% | ||
| Q2 25 | 74.2% | 67.8% | ||
| Q1 25 | 71.9% | 69.7% | ||
| Q4 24 | 76.1% | 68.2% | ||
| Q3 24 | 74.9% | 70.8% | ||
| Q2 24 | 73.8% | 68.7% | ||
| Q1 24 | 78.8% | 70.3% |
营业利润率AXGNLIVN
| Q4 25 | -16.3% | 11.8% | ||
| Q3 25 | 3.2% | 15.1% | ||
| Q2 25 | 3.0% | 15.4% | ||
| Q1 25 | -3.4% | 15.3% | ||
| Q4 24 | 4.1% | 11.5% | ||
| Q3 24 | -0.6% | 11.2% | ||
| Q2 24 | -0.9% | 12.6% | ||
| Q1 24 | -11.0% | 5.5% |
净利率AXGNLIVN
| Q4 25 | -22.0% | 8.6% | ||
| Q3 25 | 1.2% | 7.5% | ||
| Q2 25 | 1.0% | 7.7% | ||
| Q1 25 | -7.9% | -103.3% | ||
| Q4 24 | 0.9% | 17.4% | ||
| Q3 24 | -3.8% | 10.4% | ||
| Q2 24 | -4.0% | 5.1% | ||
| Q1 24 | -16.0% | -14.2% |
每股收益（稀释后）AXGNLIVN
| Q4 25 | $-0.28 | $0.57 | ||
| Q3 25 | $0.01 | $0.49 | ||
| Q2 25 | $0.01 | $0.50 | ||
| Q1 25 | $-0.08 | $-6.01 | ||
| Q4 24 | $-0.00 | $1.04 | ||
| Q3 24 | $-0.04 | $0.60 | ||
| Q2 24 | $-0.04 | $0.30 | ||
| Q1 24 | $-0.15 | $-0.78 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $41.5M | $635.6M |
| 总债务越低越好 | $48.4M | $376.1M |
| 股东权益账面价值 | $128.8M | $1.2B |
| 总资产 | $221.7M | $2.6B |
| 负债/权益比越低杠杆越低 | 0.38× | 0.31× |
8季度趋势，按日历期对齐
现金及短期投资AXGNLIVN
| Q4 25 | $41.5M | $635.6M | ||
| Q3 25 | $35.8M | $646.1M | ||
| Q2 25 | $29.9M | $593.6M | ||
| Q1 25 | $22.1M | $738.4M | ||
| Q4 24 | $33.5M | $428.9M | ||
| Q3 24 | $24.5M | $346.4M | ||
| Q2 24 | $21.1M | $329.2M | ||
| Q1 24 | $17.6M | $309.2M |
总债务AXGNLIVN
| Q4 25 | $48.4M | $376.1M | ||
| Q3 25 | $48.2M | $434.5M | ||
| Q2 25 | $47.9M | $430.6M | ||
| Q1 25 | $47.7M | $628.2M | ||
| Q4 24 | $47.5M | $627.0M | ||
| Q3 24 | $47.3M | $625.5M | ||
| Q2 24 | $47.0M | $624.5M | ||
| Q1 24 | $46.8M | $623.8M |
股东权益AXGNLIVN
| Q4 25 | $128.8M | $1.2B | ||
| Q3 25 | $120.8M | $1.2B | ||
| Q2 25 | $112.3M | $1.1B | ||
| Q1 25 | $105.4M | $1.0B | ||
| Q4 24 | $103.9M | $1.3B | ||
| Q3 24 | $99.4M | $1.3B | ||
| Q2 24 | $95.7M | $1.2B | ||
| Q1 24 | $93.2M | $1.2B |
总资产AXGNLIVN
| Q4 25 | $221.7M | $2.6B | ||
| Q3 25 | $216.4M | $2.6B | ||
| Q2 25 | $205.5M | $2.5B | ||
| Q1 25 | $196.2M | $2.6B | ||
| Q4 24 | $203.7M | $2.5B | ||
| Q3 24 | $192.0M | $2.5B | ||
| Q2 24 | $188.9M | $2.5B | ||
| Q1 24 | $186.5M | $2.5B |
负债/权益比AXGNLIVN
| Q4 25 | 0.38× | 0.31× | ||
| Q3 25 | 0.40× | 0.38× | ||
| Q2 25 | 0.43× | 0.38× | ||
| Q1 25 | 0.45× | 0.61× | ||
| Q4 24 | 0.46× | 0.47× | ||
| Q3 24 | 0.48× | 0.48× | ||
| Q2 24 | 0.49× | 0.50× | ||
| Q1 24 | 0.50× | 0.51× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.0M | $82.4M |
| 自由现金流经营现金流 - 资本支出 | $1.8M | $50.2M |
| 自由现金流率自由现金流/营收 | 3.0% | 13.9% |
| 资本支出强度资本支出/营收 | 2.1% | 8.9% |
| 现金转化率经营现金流/净利润 | — | 2.67× |
| 过去12个月自由现金流最近4个季度 | $-2.9M | $173.3M |
8季度趋势，按日历期对齐
经营现金流AXGNLIVN
| Q4 25 | $3.0M | $82.4M | ||
| Q3 25 | $3.2M | $85.1M | ||
| Q2 25 | $7.7M | $62.9M | ||
| Q1 25 | $-13.2M | $24.0M | ||
| Q4 24 | $8.7M | $78.7M | ||
| Q3 24 | $3.9M | $51.0M | ||
| Q2 24 | $4.2M | $43.4M | ||
| Q1 24 | $-12.3M | $10.0M |
自由现金流AXGNLIVN
| Q4 25 | $1.8M | $50.2M | ||
| Q3 25 | $1.7M | $62.2M | ||
| Q2 25 | $7.0M | $47.8M | ||
| Q1 25 | $-13.4M | $13.2M | ||
| Q4 24 | $8.1M | $68.3M | ||
| Q3 24 | $3.3M | $32.8M | ||
| Q2 24 | $3.3M | $31.2M | ||
| Q1 24 | $-13.2M | $3.6M |
自由现金流率AXGNLIVN
| Q4 25 | 3.0% | 13.9% | ||
| Q3 25 | 2.8% | 17.4% | ||
| Q2 25 | 12.4% | 13.6% | ||
| Q1 25 | -27.7% | 4.2% | ||
| Q4 24 | 16.3% | 21.2% | ||
| Q3 24 | 6.8% | 10.3% | ||
| Q2 24 | 6.8% | 9.8% | ||
| Q1 24 | -31.9% | 1.2% |
资本支出强度AXGNLIVN
| Q4 25 | 2.1% | 8.9% | ||
| Q3 25 | 2.5% | 6.4% | ||
| Q2 25 | 1.3% | 4.3% | ||
| Q1 25 | 0.5% | 3.4% | ||
| Q4 24 | 1.4% | 3.2% | ||
| Q3 24 | 1.2% | 5.7% | ||
| Q2 24 | 1.9% | 3.8% | ||
| Q1 24 | 2.2% | 2.2% |
现金转化率AXGNLIVN
| Q4 25 | — | 2.67× | ||
| Q3 25 | 4.55× | 3.18× | ||
| Q2 25 | 13.35× | 2.32× | ||
| Q1 25 | — | — | ||
| Q4 24 | 19.41× | 1.41× | ||
| Q3 24 | — | 1.55× | ||
| Q2 24 | — | 2.65× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AXGN
暂无分部数据
LIVN
| Other | $169.4M | 47% |
| Neuromodulation Segment | $119.7M | 33% |
| Cardiopulmonary Segment | $71.8M | 20% |
